TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

NCT05948813 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

420

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC
EGFR Activating Mutation
Brain Metastases

Interventions

DRUG: TY-9591
DRUG: Osimertinib

Sponsor

TYK Medicines, Inc